Weight & Metabolic Health

Compounded vs Branded GLP-1s in 2026: What the FDA Actually Says

By the US Health Digest editorial team · Updated July 22, 2026 · Every claim linked to its primary source

Compounded GLP-1s — the cheap versions of semaglutide and tirzepatide sold by many telehealth companies — occupy a shrinking legal gray zone in 2026. The FDA has ended the shortage rules that made mass compounding legal, sent warning letters to 30 telehealth companies in March 2026, and moved to close the remaining pathway. Patients aren't the enforcement target, but anyone buying compounded GLP-1s should understand what they're buying and what happens if supply disappears.

The 60-second history

When Wegovy and Zepbound demand outran supply, both drugs went on the FDA's official shortage list — and US law allows compounding pharmacies to make copies of drugs that are in shortage. A whole telehealth industry grew inside that window, selling compounded semaglutide at a fraction of the branded price. The shortages were then declared resolved (tirzepatide in late 2024, semaglutide in early 2025), which closed the legal basis for mass copying. Major players like Hims and Ro exited compounded semaglutide; many smaller telehealth brands did not.

The full timeline

The 60-second version above compresses several years of regulatory movement into a paragraph. If you're trying to judge where this is heading — and whether a telehealth company telling you "compounded GLP-1s are perfectly legal" is giving you the whole picture — the dated sequence matters, because every step has moved in the same direction.

• The shortage years. Demand for Wegovy and Zepbound outran manufacturing capacity, and both semaglutide and tirzepatide landed on the FDA's official drug shortage list. That listing is the legal hinge of this entire story: federal law permits compounding pharmacies to prepare copies of a drug while it is in shortage. Telehealth companies built subscription businesses on that provision, marketing compounded semaglutide at a fraction of the branded cash price.
• Late 2024 — the tirzepatide shortage is declared resolved. The first domino. Once the FDA took tirzepatide off the shortage list, the legal basis for mass-producing copies of it began to close.
• Early 2025 — the semaglutide shortage is declared resolved. The same clock started for compounded semaglutide, the far bigger market. From this point on, the shortage-era justification for large-scale copying was gone for both drugs.
• 2025 — the major players exit. Hims and Ro, the most visible names in compounded semaglutide, moved away from it. Many smaller telehealth brands did not — some continued selling under new framing, which set up the next step.
• March 3, 2026 — the FDA warns 30 telehealth companies. The agency's press announcement describes warning letters over false or misleading marketing of compounded GLP-1s. This was the moment enforcement moved from policy statements to named companies.
• April 30, 2026 — rulemaking to close the last large-scale pathway. The FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the list that allows large "outsourcing facility" compounders (the 503B pathway) to produce them at scale, finding no clinical need. Legal analysts at Orrick describe the move as shutting the door on large-scale GLP-1 compounding.
• July 30, 2026 — the public comment period closes. The FDA extended the original June 29 deadline by a month; after it closes the agency reviews comments before deciding on a final rule, with no announced timing. Our news coverage tracks what happens next.

Read as a sequence, this is not a regulatory gray area drifting along — it's a lane being closed one segment at a time: shortage listings ended, the biggest sellers left, marketing enforcement began, and now the remaining bulk-production pathway is the subject of rulemaking. Nothing in the public record suggests the direction reversing.

Where the law stands in 2026

• The FDA's position on unapproved GLP-1s is explicit: compounded versions "do not undergo FDA's review for safety, effectiveness and quality before they are marketed," and the agency reports 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, many involving dosing errors.
• Enforcement has started: in March 2026 the FDA warned 30 telehealth companies about false or misleading marketing of compounded GLP-1s.
• The remaining pathway is narrowing: the FDA has proposed excluding these drugs from the list that lets large "outsourcing facility" compounders make them at scale — legal analysts describe it as shutting the door on large-scale GLP-1 compounding. Patient-specific compounding for documented clinical need (for example, a dose or formulation no branded product offers) remains legal but is a far narrower lane than the mass-market products being sold today.

What this means practically

How to tell what you're actually buying

Telehealth marketing often blurs the line deliberately. A site can show a photo of an injection pen, talk about "semaglutide, the active ingredient in Ozempic and Wegovy," and never plainly state that the product it ships is not Ozempic or Wegovy. If you're evaluating a program — or trying to work out what you're already taking — these questions cut through the framing. A legitimate provider should answer all of them without hesitation.

• "Is the medication you'll send me FDA-approved?" This is the cleanest single question. Branded products have names: Wegovy, Zepbound, Ozempic, Mounjaro. If the answer is "it's semaglutide" or "it's the same active ingredient," that's a description of a compounded product, not an approved one. The FDA is unambiguous that compounded versions "do not undergo FDA's review for safety, effectiveness and quality before they are marketed."
• "Which pharmacy compounds it, and in what state is it licensed?" A provider selling compounded medication should be able to name the pharmacy or outsourcing facility that makes it. Vagueness here is itself an answer.
• "Is it the same form as the branded drug?" The FDA has flagged products made with salt forms of semaglutide — different chemical entities from the ingredient in the approved drugs. Oral drops, troches, and other non-injectable formats have no branded equivalent and no trial behind them. Our GLP-1 glossary covers the terminology (503A, 503B, base vs. salt form) if the vocabulary is new.
• "What happens to my treatment if compounding ends?" Given the timeline above, this is not a hypothetical. A provider that has thought about its patients should describe a transition path to a branded product. A provider whose business model only works with compounded supply may not have one — and that risk lands on you, mid-treatment.
• "What does the price actually buy?" Compare the compounded subscription price against branded direct-pay programs before assuming the gap is what the marketing implies. Our reviews — including the RxFemale review and the 2026 program comparison — mark compounded versus branded sourcing for exactly this reason.

One more filter worth applying: the FTC's Gut Check reference guide lists weight-loss claims that are red flags on their face — substantial weight loss without diet or exercise, the same results for everyone, permanent loss from a product alone. It was written for media outlets screening ads, but it works just as well as a consumer checklist for telehealth landing pages.

Why "personalized dosing" marketing deserves scrutiny

After the shortages were declared resolved, a new phrase started appearing across telehealth sites still selling compounded GLP-1s: personalized. Personalized dosing, personalized formulations, medication "tailored to you." It's worth understanding why that word, specifically, took over — because it maps directly onto the one legal lane left open.

Compounding law has always included a patient-specific exemption: a pharmacy can prepare a customized version of a drug when a documented clinical need exists that no approved product can meet — a dose strength the manufacturer doesn't make, an allergy to an inactive ingredient, a formulation a patient physically can't take. That exemption exists for genuinely individual situations, decided clinician by clinician, patient by patient.

Now hold that logic against a mass-market funnel: an ad, a questionnaire, a subscription checkout — and at the end, nearly every customer receives a "personalized" compounded product. If personalization is the default output of a marketing pipeline rather than the exception arrived at through individual clinical judgment, the word is doing legal work, not medical work. The exemption's premise is that the approved product can't serve the patient; a price difference is not a clinical need, and a dose number tweaked slightly off the branded titration schedule doesn't obviously become one.

This is precisely the territory the FDA's March 2026 warning letters addressed — false or misleading marketing of compounded GLP-1s — and the Orrick analysis of the 2026 rulemaking makes clear the agency intends the remaining lane to be narrow. None of this means individualized compounding is illegitimate — it means "personalized" on a landing page is a claim to interrogate, not a reassurance to accept. Ask the questions in the section above; a real clinical rationale survives them, and a marketing rationale doesn't.

If you're taking a compounded GLP-1 now

Don't panic, and don't stop abruptly without talking to a clinician — but do have a continuity plan: know which branded option and which provider you'd switch to if your current source disappears, and price it in advance. If you're choosing a program today, weigh the discount against the supply risk honestly — our 2026 program comparison marks which programs sell compounded versus branded medication for exactly this reason.

If you're a current patient: the continuity checklist

"Have a continuity plan" is advice that only helps if it's concrete. Here is the checklist we'd want any patient on a compounded GLP-1 to work through with their clinician — ideally before enforcement or a supply decision forces the issue.

1. Do not stop on your own. Whatever happens to your supplier, an abrupt, unplanned stop is the worst-managed version of this transition. Appetite and weight effects don't simply hold after discontinuation — we cover what the evidence shows in our guide to stopping GLP-1s and weight regain. Any change should be a decision you make with a prescriber, not one made for you by a closed pharmacy.
2. Write down exactly what you're taking. Product name as it appears on the label, the compounding pharmacy, your current dose, and your titration history. If your telehealth portal disappears, that record goes with it — export or screenshot it now.
3. Ask your current provider the continuity question directly. "If you can no longer supply compounded semaglutide or tirzepatide, what happens to my treatment?" Get the answer in writing. A transition protocol to a branded product is a good answer; silence or reassurance without specifics is not.
4. Price your branded fallback today, not during a crisis. Identify which branded product your clinician would move you to and what it would cost you through insurance and through the manufacturers' direct-pay programs. The gap between compounded and branded pricing has narrowed since the shortage era — verify the current numbers for your situation rather than relying on what the gap was when you started.
5. Line up a prescriber who isn't tied to the compounded product. If your only clinical relationship is with the telehealth company that sells the medication, your prescriber and your supply fail together. A primary care physician or an independent telehealth clinician who can prescribe branded GLP-1s is your redundancy.
6. Report problems through the official channel. If you experience an adverse event on a compounded product, tell your clinician and report it to the FDA — the agency's adverse event reporting on compounded GLP-1s is part of what drives its risk picture, and dosing errors feature heavily in what has been reported so far.
7. Decide your own exit criteria in advance. Agree with your clinician on what would trigger a switch — a warning letter naming your provider, a pharmacy closure, a formulation change, or simply the 503B rulemaking being finalized. Deciding the trigger while calm beats improvising while your refill is stuck.

If you're earlier in the process — still comparing programs, or sorting out whether a GLP-1 is right for you at all — start with our GLP-1 FAQ for women and the 2026 telehealth program comparison. The compounded-versus-branded question is one input into that decision, but in 2026 it's an input with a clock on it.